10-QPeriod: Q2 FY2008

BIOGEN INC. Quarterly Report for Q2 Ended Jun 30, 2008

Filed July 22, 2008For Securities:BIIB

Summary

Biogen Idec Inc. reported solid financial results for the first six months of 2008, with total revenues reaching $1,935.6 million and net income at $369.7 million. The company experienced significant revenue growth driven by strong performance in TYSABRI and RITUXAN, supplemented by price increases in AVONEX. This growth was partially offset by increased research and development (R&D) expenses for clinical trials and higher selling, general, and administrative (SG&A) costs associated with supporting product sales and expansion. The company's product portfolio is heavily reliant on AVONEX and RITUXAN, which accounted for approximately 82% of total revenues in the first half of 2008. TYSABRI showed particularly strong growth, indicating increasing market acceptance and potential to diversify revenue streams. Management anticipates continued higher R&D and SG&A expenses in the latter half of 2008 to support global expansion and product development. Biogen Idec maintained a healthy liquidity position with total cash, cash equivalents, and marketable securities at $1,583.3 million as of June 30, 2008, and sufficient working capital.

Financial Highlights

28 data points
Beta

Revenue

$993.44M

90.7% Gross Margin

Net Income

$206.63M

20.8% Net Margin

EPS (Diluted)

$0.70

Cash & Equivalents

$466.49M

Free Cash Flow

$485.91M

Financial Statements
Beta
Revenue$993.44M
Cost of Revenue$92.40M
Gross Profit$901.04M
R&D Expenses$252.26M
SG&A Expenses$245.69M
Operating Expenses$696.65M
Operating Income$296.80M
Net Income$206.63M
EPS (Basic)$0.71
EPS (Diluted)$0.70
Shares Outstanding (Basic)290.36M
Shares Outstanding (Diluted)293.48M

Key Highlights

  • 1Total revenue for the first six months of 2008 increased to $1,935.6 million, up from $1,489.1 million in the same period of 2007.
  • 2Net income for the first six months of 2008 was $369.7 million, with diluted EPS of $1.24.
  • 3TYSABRI sales demonstrated substantial growth, with revenues increasing by 238.7% to $261.8 million for the first six months of 2008 compared to the prior year.
  • 4AVONEX revenues grew to $1,063.3 million for the first six months of 2008, driven by price increases and favorable exchange rates in international markets, though U.S. demand saw a slight decrease.
  • 5R&D expenses increased significantly by 24.6% to $510.5 million for the first six months of 2008, reflecting investments in various pipeline projects.
  • 6SG&A expenses also rose by 17.8% to $461.5 million for the first six months of 2008, primarily due to increased international sales and marketing efforts.
  • 7The company's cash, cash equivalents, and marketable securities stood at $1,583.3 million as of June 30, 2008, providing strong liquidity despite debt repayments and share repurchases.

Frequently Asked Questions

Revenue growth was primarily driven by the strong performance of TYSABRI, which saw a significant increase in sales due to growing patient adoption. AVONEX also contributed through price increases and favorable foreign exchange rates. Additionally, RITUXAN revenues from the unconsolidated joint business arrangement showed an increase.

As of June 30, 2008, Biogen Idec had $1,583.3 million in cash, cash equivalents, and marketable securities. The company's total outstanding borrowings decreased to $1,049.6 million from $1,563.0 million at the end of 2007, following significant debt repayments, including a $1.5 billion term loan facility.

The company is heavily reliant on AVONEX and RITUXAN for a significant portion of its revenue. Near-term growth is also dependent on the market acceptance and sales growth of TYSABRI, which faces safety profile considerations and increasing competition. Long-term success hinges on the development and commercialization of other products from its R&D pipeline. Adverse safety events, competitive pressures, regulatory changes, and manufacturing issues are also identified as significant risks.

Management anticipates that both R&D and SG&A expenses will continue to be higher in 2008 compared to 2007. This increase is attributed to ongoing clinical trials and R&D projects, as well as expanded sales and marketing efforts to support the global commercialization of AVONEX and the growth of TYSABRI.